Analysts parsed the limited data available for Pfizer’s obesity candidate on the pharma’s fourth-quarter earnings call Tuesday, looking for any nugget of additional context.

With Lykos’ regulatory failure now squarely in the rearview mirror, Compass Pathways and Definium are leading what one ...

Skye Bioscience has published 52-week data on its investigational obesity drug combination, linking the cocktail to 22.3% ...

Miners and energy weigh; uranium stocks dive after AMD result; Goldman Sachs tips first earnings growth since FY22; Elders’ ...

1) the active drug substance Axitinib, which used to belong to Pfizer, is an FDA-approved, oral, potent VEGFR inhibitor. So ...

Is there another beat-and-raise in the pharmaceutical giant's near future?

Insmed Incorporated reported $144.6M in Q4 Brinsupri sales, 4.6% TAM penetration, and a 2026 Arikayce market trial expansion.

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is one of the best strong buy stocks to invest in under $5. Needham maintained a ...

Pharming Group (NASDAQ:PHAR) outlined its 2026 financial guidance and provided updates on its commercial portfolio and late-stage pipeline during its 2026 Investor Day, emphasizing continued revenue ...

Overview AI is speeding up drug discovery by analyzing large biological and chemical data in a short time.Deep learning and AI systems help design new drug mole ...

In the second chunky biotech raising so far this year, PYC Therapeutics is seeking $650 million via a placement and ... Read ...

Health systems are turning to the virtualization capability of IT platforms to gain visibility into sensitive data and streamline operations.